These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 32347023)

  • 1. Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction.
    Kim NH; Kim SG
    Diabetes Metab J; 2020 Apr; 44(2):213-221. PubMed ID: 32347023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Oct; 11():125. PubMed ID: 23057687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease?
    Fruchart JC; Hermans MP; Fruchart-Najib J
    Curr Atheroscler Rep; 2020 Jul; 22(8):43. PubMed ID: 32671476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of fibrate treatment in dyslipidemia: an overview.
    Katsiki N; Nikolic D; Montalto G; Banach M; Mikhailidis DP; Rizzo M
    Curr Pharm Des; 2013; 19(17):3124-31. PubMed ID: 23317397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists.
    Fruchart JC
    Cardiovasc Diabetol; 2013 May; 12():82. PubMed ID: 23721199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between triglyceride and high-density lipoprotein cholesterol change following fibrate therapy.
    Collins MW; König CS; Abbas A; Jewkes C; Jones AF; Ramachandran S
    Diabetes Metab Syndr; 2014; 8(4):212-5. PubMed ID: 25301006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits and risks of the treatment with fibrates--a comprehensive summary.
    Okopień B; Bułdak Ł; Bołdys A
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1099-1112. PubMed ID: 30328735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk.
    Nikolic D; Castellino G; Banach M; Toth PP; Ivanova E; Orekhov AN; Montalto G; Rizzo M
    Curr Pharm Des; 2017 Mar; 23(6):894-902. PubMed ID: 27719644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.
    Lee M; Saver JL; Towfighi A; Chow J; Ovbiagele B
    Atherosclerosis; 2011 Aug; 217(2):492-8. PubMed ID: 21592479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors.
    Ballantyne CM
    Clin Cornerstone; 2007; 8 Suppl 6():S6-13. PubMed ID: 17948362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertriglyceridemia Therapy: Past, Present and Future Perspectives.
    Canfora I; Pierno S
    Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.
    Yanai H; Adachi H; Hakoshima M; Katsuyama H
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
    Chapman MJ; Redfern JS; McGovern ME; Giral P
    Pharmacol Ther; 2010 Jun; 126(3):314-45. PubMed ID: 20153365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrates in the management of atherogenic dyslipidemia.
    Okopień B; Buldak L; Bołdys A
    Expert Rev Cardiovasc Ther; 2017 Dec; 15(12):913-921. PubMed ID: 29183206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
    Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
    Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
    Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM
    JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis.
    Bruckert E; Labreuche J; Deplanque D; Touboul PJ; Amarenco P
    J Cardiovasc Pharmacol; 2011 Feb; 57(2):267-72. PubMed ID: 21052016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.